Categories: News

Suisse Life Science SA Becomes LIFEdata SA

The iDDNA� brand and technology are now part of LIFEdata digital health services.

Lugano, Switzerland, December 17, 2018 –(PR.com)– Suisse Life Science SA, a Swiss private company, creator of the iDDNA® brand, has finally become LIFEdata.AI SA in a management buy out operation started in April 2018.

All Suisse Life Science assets will be integrated into LIFEdata digital health BU.

The iDDNA® from Suisse Life Science is a Connected Health Technology that uses DNA and data from consumer devices to help people taking an active role in managing their health and lower healthcare costs.

LIFEdata’s technology helps companies and institutions by providing a comprehensive nutritional, metabolic and lifestyle analysis and management program that includes nutrition intake and lifestyle monitoring, followed by a personalized nutritional, chronic disease prevention and fitness recommendations, tailored for the user, informed on their biomarkers and updated – in real-time – with life data from consumer devices (smartphones, wearables…).

Following the rebranding, all social media assets of Suisse Life Science will be rebranded in LIFEdata.

Let’s block ads! (Why?)

Miscw.com

Recent Posts

Gold Resource Corporation Reports Financial Results for the First Quarter 2024

DENVER--(BUSINESS WIRE)--Gold Resource Corporation (NYSE American: GORO) (the “Company”) is pleased to announce its first…

24 mins ago

Asure Announces First Quarter 2024 Results

Reports First Quarter Revenues of $31.7 Million Management Reiterates 2024 Revenue Guidance of $125.0 Million…

3 hours ago

Silvercrest Asset Management Group Inc. Reports Q1 2024 Results

NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Silvercrest Asset Management Group Inc. (NASDAQ: SAMG)…

3 hours ago

Capstone Copper Reports First Quarter 2024 Results

All amounts in US$ unless otherwise indicated VANCOUVER, British Columbia--(BUSINESS WIRE)--Capstone Copper Corp. (“Capstone” or…

3 hours ago

Magnachip Reports Results for First Quarter 2024

Financial Highlights Q1 consolidated revenue was $49.1 million, within our guidance range of $46-51 million.…

3 hours ago

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®,…

3 hours ago